Select Medical Holdings Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B), while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 59.5× Select Medical Holdings Corporation's market cap, and Select Medical Holdings Corporation pays a 1.51% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SEM | VRTX | |
|---|---|---|
Market Cap | $2.05B | $121.95B |
Sector | Health | Health |
52-Week High | $16.66 | $529.59 |
52-Week Low | $11.77 | $366.54 |
Enterprise Value | $5.01B | $116.69B |
Dividend Yield | 1.51% | — |
Signals from Pluang's Aura AI — not financial advice
Select Medical Holdings Corporation (SEM) trades at $16.51, unchanged on the day, following its recent acquisition completion by a consortium led by Robert A. Ortenzio and Martin F. at $16.50 per share. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported 2025 revenue of $5.45 billion with a net income margin of 2.42%, while valuation ratios like a P/E of 15.43 and P/S of 0.36 appear reasonable. Recent earnings show two misses in the last three quarters against expectations.
The investment outlook is dominated by the completed acquisition, effectively capping upside near the $16.50 deal price. Risks include ongoing shareholder litigation alleging fiduciary breaches by the board regarding the buyout fairness. Analyst sentiment is neutral with a Hold-heavy consensus, while the stock's future price action will largely hinge on legal outcomes surrounding the acquisition terms rather than operational performance.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →